您的位置：首页 > 产品中心 > 2240-28-0， 倍他米松21-戊酸酯
倍他米松21-戊酸酯
Betamethasone Valerate Related Compound A
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4116768 | 100 mg | 6660 |
产品别名
2240-28-0
倍他米松21-戊酸酯
Betamethasone Valerate Related Compound A
Betamethasone 21-valerate
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C27H37FO6 |
| Molecular weight | 476.58 |
| MDL number | MFCD00271767 |
| General description【一般描述】 | Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards |
| Analysis Note【分析说明】 | These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available. |
| Other Notes【其他说明】 | This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. |
产品性质
| Quality Level【质量水平】 | 300 |
| grade【等级】 | certified reference material pharmaceutical secondary standard |
| CofA | current certificate can be downloaded |
| packaging【包装】 | pkg of 100 mg |
| application(s) | pharmaceutical |
| pharmacopeia traceability【药典可追溯性】 | traceable to USP 1069018 |
| SMILES string | CCCCC(=O)OCC(=O)[C@@]1(O)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C |
| InChI | 1S/C27H37FO6/c1-5-6-7-23(32)34-15-22(31)27(33)16(2)12-20-19-9-8-17-13-18(29)10-11-24(17,3)26(19,28)21(30)14-25(20,27)4/h10-11,13,16,19-21,30,33H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1 |
| InChI key | FEROCCAEIIKMJT-SUYDQAKGSA-N |
安全信息
| Pictograms【象形图】 | GHS08 |
| Signal word【警示用语：】 | Danger |
| Hazard Statements | H360FD - H373 |
| Precautionary Statements | P202 - P260 - P280 - P308 + P313 - P405 - P501 |
| Hazard Classifications【危险分类】 | Repr. 1B - STOT RE 2 |
| Storage Class Code【储存分类代码】 | 6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects |
| WGK | WGK 3 |
